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Importance of Vaccination, Vaccine Epidemiology, 
Risk for Infections, and Current Status in the 
World and in Turkey
Cardiovascular disease (CVD) is the leading cause of 
mortality in the world and accounted for 31% of all 
global deaths in 2015.[1] The medical and economic 
burden associated with CVD is expected to increase 
in the future with increasing life expectancy. The risk 
for community-acquired pneumonia (CAP) has been 
reported to be 3.3 times higher, and invasive pneu-
mococcal disease (IPD) has been reported to be 9.9 
times higher in patients suffering from chronic heart 
conditions, including congestive heart failure, CVD, 
and valvular heart disease, when compared with in-
dividuals who have a sound cardiovascular system.[2] 
CAP (pneumococcal pneumonia, in particular) may 
require hospital admission, and the reported clinical 
and economic burden of CAP is significant. The risk 
for pneumonia-related hospital admission has been 
shown to be higher in patients who have chronic heart 
failure (HF) compared with those who do not (Odds 
ratio: 1.81; 95% confidence interval [CI]: 1.76–1.86).
[3] CAP-related mortality rates are elevated among the 
elderly and in patients 
with comorbidities.[4] 
Streptococcus pneu-
moniae is the most 
frequently isolated 
pathogen in adult pa-
tients with CAP. In-
creasing antimicrobial 
resistance in pneu-
mococci worldwide 
further increases the 
burden of the disease.
[5] The World Health 
Organization (WHO) has recommended investigating 
and developing new antimicrobials against S. pneu-
moniae as one of the global priority pathogens.[6] 
The prevalence of concurrent chronic heart con-
ditions in adult patients with CAP varies from 10% 
to 47% in Europe.[7] The prevalence of concurrent 
chronic heart conditions in CAP has been reported 
to be 19.9% in Asian countries.[8] There are reports 
indicating that patients with pneumonia may develop 
cardiac complications during the acute stage of the 
disease[9–12] and that the long-term risk of developing 
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CVD may be increased.[13,14] The risk of developing 
CVD is increased 6-fold in adults during the first year 
after a hospital admission associated with pneumonia 
or sepsis (adjusted risk [hazard] ratio: 6.33; 95% CI: 
5.65–7.09). Although the risk for CVD gradually de-
clines over time, the risk for CVD remains high even 
5 years after such infections (adjusted risk ratio: 1.87; 
95% CI: 1.47–2.38).[15]
In addition to general measures for health protec-
tion (personal hygiene, clean drinking water, waste 
management, etc.), active and passive immunization 
is also important in the protection against infections. 
Active immunization (vaccination) is the most ef-
fective and inexpensive method to fight vaccine-pre-
ventable infection.[16] The main goal of vaccination is 
to reduce the risks for disease, disability, and death, 
and to ensure the maintenance of overall health. The 
incidence of vaccine-preventable disease declined by 
more than 99% in the 20th century as a result of vacci-
nation programs, and certain diseases have even been 
eradicated.[17] Currently, there are many infectious dis-
eases with high mortality and morbidity rates (pneu-
mococcal pneumonia, influenza, measles, varicella, 
hepatitis A, hepatitis B, rubella, tetanus, etc.) that 
may occur in adults. The administration of booster 
doses to adults who received childhood vaccines and 
the participation of adults who never received child-
hood vaccines in adult vaccination programs are of 
paramount importance.[18] Regular adult vaccination 
may help reduce the mortality and morbidity associ-
ated with vaccine-preventable diseases, particularly 
in the elderly.[19,20] Vaccination may also help fight 
antimicrobial resistance. A reduction in the incidence 
of infectious disease can reduce antimicrobial usage 
and indirectly lead to a reduction in the prevalence of 
resistant species.[21]
Cardiac events may have a negative impact on 
short- and long-term mortality rates in patients with 
pneumonia.[11,12,22] Mortality rates in patients with 
pneumococcal pneumonia and concurrent cardiac 
events (myocardial infarction, severe arrhythmias, 
new or worsening congestive HF) have been reported 
to be higher compared with the mortality rates of pa-
tients with pneumonia alone.[23] Furthermore, the 10-
year survival rate (other than patients who die within 
the first month) after having pneumococcal pneumo-
nia has been demonstrated to be lower compared with 
age- and sex-matched individuals.[24] 
The efficacy of the 13-valent pneumococcal conju-
gate vaccine (PCV13) in protecting against CAP and 
IPD in adults has been well established.[25] Pneumonia 
requiring hospital admission is associated with a high 
mortality rate in the elderly: It has been recorded as 
10.7% in those who had received the PCV 13 vaccine 
previously, 14.1% in patients who had received the 
23-valent pneumococcal polysaccharide vaccine, and 
16.4% in patients who had never been vaccinated.[26]
Before the introduction of PCV13 in our country 
(from 1996 to 2008), the potential coverage of PCV13 
was estimated to be 71.5% of all pneumococcus 
strains responsible for IPD in adults.[27] The combined 
use of PCV13 and PPV23 according to a vaccination 
schedule is designed to increase the efficacy and cov-
erage of these vaccines. 
Influenza is one of the leading causes of mortal-
ity and morbidity among infectious diseases. Patients 
with chronic diseases, such as diabetes and CVD, are 
more likely to develop complications associated with 
influenza infections. Considering the distribution of 
chronic diseases in Turkey, the estimated number of 
people to be included in high-risk groups for influenza 
varies from 27 to 33 million people.[28] A number of 
cardiovascular complications of influenza infections 
have been reported.[29] Influenza infections have a 
negative impact on acute/chronic HF. Annual vacci-
nation against influenza has been considered an effec-
tive measure for secondary prevention of HF.[30,31] The 
association between an annual vaccination against 
influenza and lower rates of repeated hospital admis-
sions[32] and a reduced risk for all-cause mortality has 
been demonstrated in patients with chronic HF.[33–35]
Current status in our country and other countries 
Various vaccine coverage rates have been reported in 
regional studies or studies conducted in specific pa-
tient groups, but what all of these studies have in com-
mon is that the coverage rates are much lower than 
desired. 
Important study sites from our country took part in 
the international PARADIGM-HF trial (Prospective 
comparison of ARNI with ACEI to Determine Impact 
on Global Mortality and morbidity in Heart Failure). 
Of more than 8000 participants with HF and a reduced 
ejection fraction, only 21% had received an influenza 
vaccine within the year before their participation in 
this study, and 79% had not received an influenza 
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vaccine in the same period of time. The highest vac-
cine coverage rate was reported from the Netherlands, 
with 77.5%, while only 1.6% of participants from our 
country had received an influenza vaccine.[35] The re-
sults of this study clearly reflect how low the vacci-
nation rate is in patients with CVD in our country. 
Although no specific data are available for pneumo-
coccal vaccine coverage among patients with chronic 
heart conditions, these rates are also expected to be 
very low. The pneumococcal vaccine coverage rate in 
patients with chronic obstructive pulmonary disease 
(COPD) was determined to be 15% and the influenza 
vaccine coverage rate was found to be 37% in a smal-
l-scale study conducted in our country.[36] The rate of 
awareness of influenza and pneumococcal vaccines 
was 49% and 12%, respectively, and the immuniza-
tion coverage rate for these vaccines was found to be 
40% and 10% among patients with COPD in a study 
conducted in Izmir in 2008.[37] In a study assessing the 
impact of physician awareness about influenza and 
pneumococcal vaccines on coverage rates for these 
vaccines among their patients with diabetes, after be-
ing assessed for their knowledge about current vacci-
nation practices, physicians participated in a training 
program. The results indicated that 87.9% and 83.4% 
of the patients with diabetes had been recommended 
to get the influenza vaccine and the pneumococcal 
vaccine, respectively, over the previous 5 years, and 
only 27% actually received the influenza vaccine and 
9.8% received the pneumococcal vaccine. One year 
after the training program, the physicians’ vaccine 
recommendation rate increased to 97.6% and 95.1%, 
respectively, and the vaccine coverage rate increased 
to 63.3% and 40.7% for the influenza and pneumo-
coccal vaccines, respectively.[38]
Therefore, primary and secondary preventive 
measures for CVD patients should be reviewed more 
comprehensively. The Center for Population Health 
and Aging, founded with the support of the Centers 
for Disease Control and Prevention (CDC), in 2001 
announced “10 Key Measures” to healthy aging.[39] 
Regular immunization is among these measures. The 
vaccines recommended by the CDC for adults include 
those for influenza, diphtheria, pertussis, tetanus, vari-
cella, human papillomavirus, herpes zoster (shingles), 
rubella, measles, mumps, pneumococcal disease 
(PCV13, PPV23), meningococcal disease, hepatitis 
A, hepatitis B, and Haemophilus influenza type B.[40]
Although immunization of adults at risk has been 
widely neglected, this issue is of paramount impor-
tance. The number of those receiving adult immu-
nizations is far from the desired level, in spite of its 
proven benefits.[41–43] Adult vaccination coverage is 
substantially lower than the global average. 
The aim of this consensus report was to raise 
awareness about the immunization of adults and el-
derly people with chronic heart conditions who are 
at risk for infectious diseases with high mortality and 
morbidity, such as influenza and pneumococcal infec-
tions, in the context of the fight against CVD and to 
provide guidance to health professionals on why and 
how to vaccinate this population.
Background Information On Heart Conditions 
and Vaccination 
The mechanism of heart failure associated with
influenza and pneumococcal infections 
Acute respiratory infections such as pneumonia may 
lead to acute heart conditions. Extension of inflamma-
tion induced by respiratory infections may accelerate 
atherogenesis and disturb the inotropic state. Pro-inflam-
matory cytokines, such as interleukins, tumor necrosis 
factor alpha, and C-reactive protein, enhance the ex-
pression of cell adhesion molecules on endothelial sur-
faces. Increased adhesion molecules promote the migra-
tion of leukocytes into the intima. This process results 
in lipoprotein oxidation in the atherogenesis cascade.
[44,45] In pneumonia, circulating inflammatory mediators 
(such as cytokines, endotoxins) may lead to left ventric-
ular dysfunction through a direct myocardial depressing 
effect.[18] Increased cytokine expression associated with 
influenza infections may lead to myocardial remodeling 
and overproduction of tissue inhibitors of matrix met-
alloproteinases. These processes may contribute to left 
ventricular dilatation and the HF phenotype by increas-
ing collagen content in myocardial tissue.[46]
Susceptibility to pneumonia in adult patients with 
heart disorders 
Chronic CVD and lung diseases are among the lead-
ing predisposing factors for pneumonia. An epidemi-
ological study demonstrated that heart diseases were 
the most important risk factors for pneumonia in adult 
patients over the age of 60 and among heart condi-
tions, chronic compensated HF posed the highest risk 
for pneumonia.[47] Patients with HF are at a substan-
tially higher risk for pneumonia for a number of rea-
sons. Alveolar edema increases the risk for microbial 
clearance and bacterial infections by blocking the 
normal physiological mechanisms of the alveolar bed 
between air and lung tissue.[48] It has been reported 
that 23.7% of patients with pneumonia suffer from HF 
and that the presence of HF increases the risk of de-
veloping pneumonia 1.9-fold.[49] Although pneumonia 
is known to cause acute decompensation of HF, this 
study concluded that chronic decompensated HF in-
creased the risk for developing pneumonia, pneumo-
nia-related hospital admission, and deaths. These data 
demonstrate a reciprocal relationship between pneu-
monia and HF. Another case control study demon-
strated that among a variety of heart diseases, only 
HF was a risk factor for pneumonia (Relative risk: 
5.69; 95% CI: 1.69–19.04; p=0.0048) and both acute 
HF and chronic HF increase this risk. Furthermore, a 
close relationship was found between ventricular dys-
function and the development of pneumonia.[50] 
In a large, prospective, controlled study of 4988 
patients who were diagnosed with CAP without HF, 
the mean age was 55 years. The patients were fol-
lowed up for 10 years. The incidence of HF was de-
termined to be 11.9% in the pneumonia group and 
7.4% in the control group (p<0.001). However, the 
hospital admission rate for HF within 90 days and 1 
year after discharge from the hospital was found to 
be significantly higher in the pneumonia group than 
in the control group.[14] The risk of developing pneu-
monia was 3.8 times higher in patients with chronic 
heart diseases according to a retrospective assessment 
of data from between 2006 and 2010 obtained from 
the US-based healthcare database (Fig. 1).[51]
Which heart diseases necessitate adult vaccination?
Heart diseases for which international guidelines 
recommend vaccination against influenza and pneu-
monia and the relevant guidelines are summarized in 
Table 1. Adult patients with any of the following dis-
eases may benefit from vaccination. 
1. Heart failure and cardiomyopathy 
2. Atherosclerotic heart diseases
3. Valvular heart diseases
4. Cyanotic congenital heart diseases 
5. Pulmonary arterial hypertension 
Commercially Available Vaccines, Side Effects, 
Contraindications of the Influenza Vaccine
The specific formula of the annual seasonal influenza 
vaccine is determined by the World Health Organiza-
tion (WHO). The virus types thought most likely to 
circulate during the upcoming season are targeted and 
vaccine manufacturers are informed. Trivalent and 
quadrivalent vaccines are made available. Trivalent 
vaccines protect against 2 influenza A species and an 
influenza B species, while quadrivalent vaccines are 
also protective against another influenza B species in 
addition to those included in trivalent vaccines. 
Inactive influenza vaccines (IIV): IIV are produced 
by highly purified and inactivated viruses grown in 
embryonated eggs. The preservative, ethyl mercury 
(thiomersal), is only included in inactivated vaccines 
supplied in multi-dose vials of inactivated vaccines 
that do not contain aluminum as an adjuvant. Single-
dose vaccines (in prefilled syringes) that are available 
in our country for routine use do not contain thiom-
ersal. Vaccine-induced protection starts from 2 to 4 
weeks after vaccination and continues throughout the 
flu season (6 to 8 months) (CDC). 
Side effects
The side effects associated with influenza vaccines 
are usually mild and spontaneously resolve within a 
few days. The most common side effects include pain, 
erythema and swelling at the injection site, headache, 
pyrexia, nausea, and myalgia. Fainting may occur, 
as with any other injection. Although some studies 
have reported an association between the vaccine 
and Guillain-Barré syndrome, this association has not 
been determined in other studies; however, influenza 
infections may also induce Guillain-Barré syndrome. 
The prevalence of Guillain-Barré syndrome has been 
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Figure 1. Increased risk for pneumonia according to under-
lying disease. Adapted from Koivula et al.[49]
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Table 1. Vaccines recommended by international guidelines 
Author
European Society of Cardiology
American Heart Association/ American 
College of Cardiology
Heart Failure Society of America
Centers for Disease Controls
Guidelines
2015 Guidelines for Pulmonary
Hypertension[52]
2011 Secondary Prevention and Risk 
Reduction Therapy in Patients with 
Coronary and Other Atherosclerotic 
Vascular Diseases[55]
2010 Clinical Practice Guidelines for 
Heart Failure[58]
Advisory Committee on Immunization 
Practices[59]
2013 Guidelines for the Management 
of Heart Failure[56]
2014 Guidelines on Valvular Heart 
Disease[57]
2016 Guidelines on Cardiovascular 
Disease Prevention in Clinical
Practice[53]
2016 Guidelines on Diagnosis and 
Treatment of Acute and Chronic Heart 
Failure[54]
Recommendations
Immunization of patients with
pulmonary arterial hypertension 
against influenza and pneumococcal 
infections is recommended
(Class I; Evidence Level C)
Annual influenza vaccination of
patients with cardiovascular disease
is recommended
(Class I; Evidence Level B)
Immunization against influenza and 
pneumococcal infections is
recommended for all patients with 
heart failure, if not contraindicated 
(Evidence Level B)
Annual inactive influenza vaccination 
of adult patients with chronic
pulmonary and cardiovascular
diseases is recommended
Polysaccharide pneumococcal
vaccines are recommended for all 
adults aged >65 years and younger 
patients with high-risk
immunocompetent diseases, such 
as chronic cardiovascular diseases 
(except hypertension)
Vaccines against influenza and
pneumococcal infections are
recommended for secondary
prevention
Immunization against influenza and 
pneumococcal infections is
recommended for groups of eligible 
patients with valvular heart disease
Annual influenza vaccination of 
patients with proven cardiovascular 
disease is recommended
(Class IIb; Evidence Level C)
Immunization against influenza and 
pneumococcal infections may be
considered
reported to be 9-fold less in vaccinated populations 
compared to unvaccinated populations (CDC).
Contraindications
• People who develop a severe allergic reaction to 
any component of inactive or recombinant in-
fluenza vaccines or people who have had an aller-
gic reaction to any prior influenza vaccination; 
• People who have had an anaphylactic-type egg al-
lergy reaction;
• Vaccination should be postponed in people with 
moderate to severe acute disease (with or without 
fever) and those who have been diagnosed with 
Guillain-Barré syndrome in the last 6 weeks.
Recombinant influenza vaccine: This vaccine is 
produced using third-generation production technol-
ogy, and was approved for use and introduced in 2013 
in the US. It is not yet available in our country. This 
technology does not require an egg-grown vaccine 
virus. Recombinant influenza vaccine is the only vac-
cine that is 100% egg-free. 
Live attenuated flu vaccine: The content (other 
than live viruses) of the vaccine and the timing of 
the administration is the same as that of inactive vac-
cines. As this vaccine is adapted to cold temperatures, 
it should be stored at ≤-15°C. The vaccine is given as 
an intranasal spray and induces both mucosal and sys-
temic immunity. The WHO did not recommend this 
vaccine for the 2017–2018 season. Live attenuated 
vaccines are not available in our country.
Characteristics of pneumococcal vaccines 
PCV13: PCV13 is a conjugated vaccine that protects 
against 13 types of Streptococcus pneumoniae. Con-
jugated pneumococcal vaccines are covalently con-
jugated pneumococcal, antigenic, capsular polysac-
charides, and non-toxic proteins (CRM 197, Protein 
D) of bacteria, such as diphtheria and Haemophilus 
influenza. The most important characteristic of con-
jugated vaccines is to induce strong immunogenicity 
associated with the conjugated protein. These proteins 
cause a better antibody response through a T-cell-
mediated immune response and mucosal immunity 
(through secretory immunoglobulin A production), 
as well as immunological memory cell response.[31] 
Therefore, PCV13 may induce long-lasting immunity 
in both children and adults. 
PCV13 is used to provide protection against the 
inflammation of meninges (meningitis), the fever and 
chills associated with bacteria that enter the blood-
stream (sepsis), and the presence of bacteria or bacte-
rial toxins in the circulating blood (bacteremia), and 
lung inflammation (pneumonia) caused by Strepto-
coccus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 
9V, 14, 18C, 19A, 19F, and 23F.[60] PCV13 is available 
as a 0.5 mL suspension in a single-use, prefilled sy-
ringe for intramuscular injection.
Side effects
Although no severe effects have been observed with 
PCV13, it may induce some mild symptoms, such 
as erythema, swelling, pain or tenderness, pyrexia, 
decreased appetite, irritability, fatigue, headache, or 
chills. 
Contraindications
PCV13 should not be administered to individuals with 
• A prior history of allergic reactions to PCV13 or 
PCV7, 
• A prior history of allergic reaction to any vaccine 
that contained diphtheria toxoid, 
• Allergic reaction to any component of PCV13. 
• Caution should be taken with individuals who 
have a history of severe allergic reactions or life-
threatening allergic reactions. The vaccine can be 
administered to individuals suffering from a mild 
common cold; however, administration of the vac-
cine should be postponed until recovery in those 
who have a severe health condition. 
PPV23: PPV23 is a polysaccharide vaccine that 
provides protection against 23 types of Streptococcus 
pneumoniae. The mechanism of action of polysac-
charide vaccines is completely based on the humoral 
immune response. PPV23 does not stimulate T-cells; 
therefore, immunological memory does not occur. 
Antibody response occurs within 2 to 3 weeks, and 
this response may show individual variations. The 
serum antibody level is directly related to the level 
of protection. Serum antibody levels rapidly decline 1 
to 2 years after the vaccination in people over the age 
of 50, and antibodies persist at low levels for up to 10 
years.[8–11] Revaccination may be required, as persis-
tent immunological memory does not occur. Although 
revaccination may provide an ongoing antibody re-
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sponse in healthy adults and the elderly, vaccines 
given at short intervals may cause a decline in the an-
tibody level.[10,12] Therefore, revaccination should be 
performed at least 5 years after the initial vaccination.
PPV23 is used to provide protection against in-
flammation of the meninges (meningitis), fever, and 
the chills associated with bacteria that enter the blood-
stream (sepsis) or the presence of bacteria or bacterial 
toxins in the circulating blood (bacteremia) and lung 
inflammation (pneumonia) caused by Streptococcus 
pneumoniae serotypes 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 
10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 
23F, and 33F.[60] 
Side effects
Erythema, pain, fever, and myalgia may occur, which 
usually resolve spontaneously.
Contraindications
• PPV23 should not be given to people who have a 
history of allergic reaction to PPV23 or any com-
ponent of PPV23;
• Although a mild, common cold does not typically 
prevent patients from receiving PPV23, the vacci-
nation should be postponed until recovery in those 
with severe disease; 
• Although no adverse effects have been demon-
strated in pregnant women or infants born to a 
mother reporting vaccination during pregnancy, 
women are recommended to receive the vaccine 
before becoming pregnant as a precaution. 
Side effects that may occur following any vaccination
Although severe allergic reactions may occur follow-
ing any vaccination, the risk of developing such a re-
action has been reported as 1/1,000,000. These reac-
tions may occur within a few minutes or a few hours 
after vaccination. While there is a degree of risk, as 
with any medicinal product, the vaccine-related risk 
of severe damage or death is very small.
How to Administer? 
Turkish Ministry of Health recommendations on 
vaccinations
In 2016, the Turkish Public Health Institution an-
nounced that people should be vaccinated with PCV13 
and PPV23. Based on this announcement, those at risk 
included patients with heart diseases (cyanotic con-
gestive heart failure and HF, in particular), patients 
infected with HIV, immunocompromised patients, 
diseases requiring treatment with immunosuppressive 
agents, solid organ transplantations, and congenital or 
acquired immunodeficiency.[61] 
Timing of vaccinations 
Influenza vaccines should be administered to adults 
with chronic heart conditions in the autumn (prefer-
ably in October, in the northern hemisphere), though 
they may be administered until February, and should 
be repeated annually (CDC).
Unlike influenza vaccines, pneumococcal vaccines 
can be given at any time throughout the year. Both 
pneumococcal vaccines (PCV13 and PPV23) are rec-
ommended for adults.
For individuals who have not previously received 
a pneumococcal vaccine, first, a single dose of PCV13 
should be given, followed by PPV23 at least 1 year 
later, with a booster dose administered 5 years after 
the first dose of PPV23. The third dose of PPV23 
should be administered to people aged 65 years and 
older.[62,63]
For adults who are not included in the group of 
patients with HF or chronic heart conditions, the in-
terval between the 2 pneumococcal vaccines (PCV13 
and PPV23) should be at least 1 year. However, 
PPV23 can be administered 8 weeks after the PCV13 
administration in adults at high risk who need accel-
erated vaccination (immunodeficiency, asplenia, cere-
brospinal fluid leak, or cochlear implant). If PPV23 
was administered first, PCV13 should be given at 
least 1 year later.[62,63]
For patients with active infections and/or who 
are admitted to hospital for an acute
cardiac event (acute coronary syndrome,
acute heart failure, acute pulmonary
thromboembolism, etc.), pneumococcal
vaccines should be administered at
discharge from the hospital or during the first 
follow-up visit after discharge upon
recovery from the current illness and
once the patient has become
hemodynamically stable.
Access to the vaccine 
Figure 2 and Figure 3 show how to access to vaccines 
in Turkey Health System.
Use in combination with other vaccines 
• PCV13 and inactive influenza vaccine can be 
given simultaneously in adults. PCV13 and in-
active influenza vaccine are immunogenic and 
well-tolerated when administered simultane-
ously.[64] 
• Simultaneous administration with inactive in-
fluenza vaccine may promote patient compliance 
with vaccines and thereby contribute to improved 
public health.[64]
Consensus and recommendations 
Although the benefits of vaccines remained unknown, 
vaccine coverage rates are below the desired level 
in our country, as in much of the rest of the world. 
Adults and elderly patients with chronic heart con-
ditions should be vaccinated, as they are at risk for 
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Figure 2. The means of access to vaccines reimbursed by the Turkish Social Security 
Institution. SSI: Turkish Social Security Institution.
Access to vaccinnes under SSI reimbursement coverage
• Seasonal Flu Vaccines
• 23-Valent Polysaccharide Pneumococcal
 Vaccines
The vaccine is prescribed
to the patient under SSI
coverage
1 2 3
The patient goes to the
pharmacy and buys the
vaccine
The patient goes to a
healthcare facility and
gets vaccinated
Figure 3. Access to vaccines within the scope of the Expanded Programme on Immu-
nization in Turkey. ASM: Family Health Center.
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infectious diseases associated with high morbidity 
and mortality, such as influenza and pneumococcal 
infections. Figure 4 illustrates the recommendations 
on how and when to administer influenza and pneu-
mococcal vaccines to patients with HF and/or heart 
diseases. 
Recommendations to physicians 
• Perform awareness-raising activities to make vac-
cines a part of the routine practice of physicians 
and a part of treatment, 
• Conduct training sessions, meetings, etc.,
• Add vaccinations to patient record systems, such 
as discharge reports, discharge protocol and pa-
tient files, and follow up on vaccination status, 
• Share the consensus report with physicians and ap-
propriate platforms, 
• Issue vaccination bulletins.
Recommendations for patient education and
compliance
• Preparation of an immunization record card, 
• The use of printed materials, such as posters/
brochures, to raise awareness/consciousness 
Recommendations for healthcare facilities and the 
healthcare system 
• Establish a unit for immunization at outpatient 
clinics, 
• Establish special vaccination follow-up systems in 
cardiology clinics, 
• Establish an infrastructure addressing branch cen-
ters and city hospitals.
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